iPSC Technology Revolutionizes CAR-T Cell Therapy for Cancer Treatment
Chimeric Antigen Receptor (CAR)-engineered T (CAR-T) cell therapy represents a highly promising modality within the domain of cancer treatment. CAR-T cell therapy has demonstrated notable efficacy in the treatment of hematological malignancies, solid tumors, and various infectious diseases. However,...
Saved in:
Main Authors: | Jiepu Zong, Yan-Ruide Li |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2025-01-01
|
Series: | Bioengineering |
Subjects: | |
Online Access: | https://www.mdpi.com/2306-5354/12/1/60 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Alloreactive-free CAR-VST therapy: a step forward in long-term tumor control in viral context
by: Valentine Wang, et al.
Published: (2025-01-01) -
Breaking the shield of solid tumors: a combined approach for enhanced efficacy of CAR-T cells
by: Marat Khaliulin, et al.
Published: (2024-11-01) -
Risk analysis of cardiovascular toxicity in patients with lymphoma treated with CD19 CAR T cells
by: Yang Liu, et al.
Published: (2025-01-01) -
A self-activated and protective module enhances the preclinical performance of allogeneic anti-CD70 CAR-T cells
by: Zhao Zhang, et al.
Published: (2025-01-01) -
From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy
by: E. Pinto, et al.
Published: (2025-01-01)